| [1] |
Degiuli M, Sasako M, Ponti A, et al. Randomized clinical trial comparing survival after D1 or D2 gastrectomy for gastric cancer[J]. Br J Surg, 2014, 101(2): 23-31.
|
| [2] |
Lipowska-Bhalla G, Gilham DE, Hawkins RE, et al. Targeted immunotherapy of cancer with CAR T cells: achievements and challenges[J]. Cancer Immunol Immunother, 2012, 61(7): 953-962.
|
| [3] |
Yan M, Schwaederle M, Arguello D, et al. HER2 expression status in diverse cancers: review of results from 37 992 patients[J]. Cancer Metastasis Rev, 2015, 34(1): 157-164.
|
| [4] |
Guo Y, Wang Y, Han W. Chimeric antigen receptor-modified T cells for solid tumors: challenges and prospects[J]. J Immunol Res, 2016, 2016: 3850839.
|
| [5] |
杨自国，郭晓波，石玉龙, 等. 胃癌转移相关长链非编码RNA的研究进展[J]. 中国普外基础与临床杂志, 2015, 22(4): 513-516.
|
| [6] |
Maher J, Wilkie S, Davies DM, et al. Targeting of tumor-associated glycoforms of MUC1 with CAR T cells[J]. Immunity, 2016, 45(5): 945.
|
| [7] |
Cheadle EJ, Gornall H, Baldan V, et al. CAR T cells: driving the road from the laboratory to the clinic[J]. Immunol Rev, 2014, 257(1): 91-106.
|
| [8] |
Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy[J]. Nat Rev Cancer, 2016, 16(9): 566-581.
|
| [9] |
Sadelain M, Rivière I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes[J]. Nat Rev Cancer, 2003, 3(1): 35-45.
|
| [10] |
Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86(24): 10024-10028.
|
| [11] |
Hombach AA, Heiders J, Foppe M, et al. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10secretion by redirected CD4(+) T cells[J]. Oncoimmunology, 2012, 1(4): 458-466.
|
| [12] |
Fanotto V, Ongaro E, Rihawi K, et al. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives[J]. Oncotarget, 2016, 7(42): 69060-69074.
|
| [13] |
Song Y, Tong C, Wang Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo[J]. Protein Cell, 2018, 9(10): 867-878.
|
| [14] |
Han H, Wang S, Hu Y, et al. Monoclonal antibody 3H11 chimeric antigen receptors enhance T cell effector function and exhibit efficacy against gastric cancer[J]. Oncol Lett, 2018, 15(5): 6887-6894.
|
| [15] |
章浩，叶真龙，钱其军. 降低亲和力提高HER2-CAR-T细胞治疗的安全性[J]. 药学实践杂志, 2016, 34(3): 261-266.
|
| [16] |
Ahmed N, Salsman VS, Kew Y, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors[J]. Clin Cancer Res, 2010, 16(2): 474-485.
|
| [17] |
Ahmed N, Salsman VS, Yvon E, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression[J]. Mol Ther, 2009, 17(10): 1779-1787.
|
| [18] |
Sun M, Shi H, Liu C, et al. Construction and evaluation of a novel humanized HER2-specific chimeric receptor[J]. Breast Cancer Res, 2014, 16(3): R61.
|
| [19] |
Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome[J]. Blood, 2014, 124(2): 188-195.
|
| [20] |
Lamers CH, Sleijfer S, van Steenbergen S, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity[J]. Mol Ther, 2013, 21(4): 904-912.
|
| [21] |
Ertl HC, Zaia J, Rosenberg SA, et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010[J]. Cancer Res, 2011, 71(9): 3175-3181.
|
| [22] |
Xu XJ, Tang YM. Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells[J]. Cancer Lett, 2014, 343(2): 172-178.
|
| [23] |
Casucci M, Bondanza A. Suicide gene therapy to increase the safety of chimeric antigen receptor-redirected T lymphocytes[J]. J Cancer, 2011, 2: 378-382.
|